BeyondAirInc . (NASDAQ:XAIR) Director Ron Bentsur sold 4,343 shares of BeyondAirInc . stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $6.16, for a total value of $26,752.88. Following the completion of the sale, the director now directly owns 280,983 shares in the company, valued at approximately $1,730,855.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

NASDAQ XAIR opened at $6.21 on Friday. The company has a market cap of $104.58 million, a P/E ratio of -3.37 and a beta of -0.60. The company has a debt-to-equity ratio of 0.24, a quick ratio of 5.48 and a current ratio of 5.48. The business’s 50 day moving average price is $6.75 and its 200-day moving average price is $7.06. BeyondAirInc . has a fifty-two week low of $3.45 and a fifty-two week high of $12.50.

BeyondAirInc . (NASDAQ:XAIR) last released its earnings results on Monday, June 22nd. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.01). BeyondAirInc . had a negative net margin of 203.22% and a negative return on equity of 162.21%. The company had revenue of ($0.20) million for the quarter, compared to the consensus estimate of $0.45 million. As a group, equities analysts predict that BeyondAirInc . will post -1.21 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of XAIR. Geode Capital Management LLC purchased a new position in BeyondAirInc . during the 4th quarter valued at $170,000. Baldwin Brothers Inc. MA purchased a new position in BeyondAirInc . during the 1st quarter valued at $128,000. Joseph P. Lucia & Associates LLC purchased a new position in BeyondAirInc . during the 1st quarter valued at $27,000. Steward Partners Investment Advisory LLC purchased a new position in BeyondAirInc . during the 1st quarter valued at $100,000. Finally, UBS Group AG purchased a new position in BeyondAirInc . during the 1st quarter valued at $77,000. Institutional investors own 10.76% of the company’s stock.

Several research firms have recently weighed in on XAIR. Oppenheimer reissued a “buy” rating and set a $9.00 target price on shares of BeyondAirInc . in a research report on Tuesday, June 23rd. Zacks Investment Research reissued a “buy” rating and set a $9.25 target price on shares of BeyondAirInc . in a research report on Saturday, May 30th.

BeyondAirInc . Company Profile

Beyond Air, Inc, a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria.

Read More: Treasury Bonds

Insider Buying and Selling by Quarter for BeyondAirInc   . (NASDAQ:XAIR)

Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.